Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
CAMBRIDGE, Mass., May 08, 2017 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, May 15, 2017, at 5:00 p.m. ET to discuss a corporate update and results for the first quarter of 2017.
To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 17355274. A live webcast of the presentation will be available on the Investors & Media section of the Editas website at www.editasmedicine.com.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 [email protected]
